Stocktoria

Entrada Therapeutics, Inc. TRDA

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-10-29

Entrada Therapeutics, Inc. statistics & valuation

Market cap$300.5M
P / S11.8×
P / B1.0×
Net margin-565.5%
Return on equity-47.0%
FCF margin-509.6%
Return on capital-44.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-5.20% 31.10% -565.50% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-2.50% 22.30% -621.10% 202020212022202320242025
Return on equity (%)
-17.10% -44.50% -2.80% 15.30% -47.00% 202020212022202320242025
Shares outstanding
1.2M 31.2M 31.4M 33.4M 39.0M 41.4M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-60.90% -16.70% -37.50% -1.40% 12.50% -38.10% 202020212022202320242025
Free cash flow margin (%)
104.00% -21.20% -509.60% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$24.00 -$8.16 -$3.02 -$0.20 $1.68 -$3.47 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-621.1%22.3%-2.5%———
Net margin-565.5%31.1%-5.2%———
FCF margin-509.6%-21.2%104.0%———
Return on assets-38.1%12.5%-1.4%-37.5%-16.7%-60.9%
Return on equity-47.0%15.3%-2.8%-44.5%-17.1%63.9%
Current ratio12.5311.152.339.5544.4611.89

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.